CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 44.44%

Compliant submissions 4

Incompliant submissions 5

Total trials 9

My Organizations' Clinical Trials

Showing 275 of 430 entries

View as:

Early Phase II Trials for Cocaine Medication Development - 1

Phase: N/A Priority: Normal

NCT ID: NCT00000317 Org: User:

Start: 08/31/96 End: 07/31/99 Due: 07/31/00

New Approaches to Cocaine Abuse Medications (A) - 6

Phase: N/A Priority: Normal

NCT ID: NCT00000271 Org: User:

Start: 01/31/95 End: 10/31/02 Due: 10/31/03

A Laboratory Model for Heroin Abuse Medications - 8

Phase: N/A Priority: Normal

NCT ID: NCT00000273 Org: User:

Start: 08/31/95 End: 11/30/05 Due: 11/30/06

A Gender-Enhanced Pre-Exposure Prophylaxis (PrEP) Information-Motivational Workshop for Young South African Women

Phase: N/A Priority: Normal

NCT ID: NCT04833127 Org: User:

Start: 03/17/21 End: 12/31/22 Due: 12/31/23

Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression

Phase: N/A Priority: Normal

NCT ID: NCT00564278 Org: User:

Start: 02/29/08 End: 08/31/13 Due: 08/31/14

Eye Tracking as a Biomarker of Cannabis Effects

Phase: N/A Priority: Normal

NCT ID: NCT04100590 Org: User:

Start: 10/01/19 End: 01/31/20 Due: 01/31/21

Electroretinogram: a New Human Biomarker for Smoking Cessation Treatment

Phase: N/A Priority: Normal

NCT ID: NCT03213418 Org: User:

Start: 02/01/18 End: 12/01/22 Due: 12/01/23

Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1

Phase: N/A Priority: Normal

NCT ID: NCT00061087 Org: User:

Start: 02/28/98 End: 10/31/04 Due: 10/31/05

Pioglitazone for Heroin and for Nicotine Dependence

Phase: N/A Priority: Normal

NCT ID: NCT01395797 Org: User:

Start: 03/31/11 End: 06/30/14 Due: 06/30/15

Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder

Phase: N/A Priority: Normal

NCT ID: NCT04880278 Org: User:

Start: 03/01/22 End: 05/08/24 Due: 05/08/25

Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence

Phase: N/A Priority: Normal

NCT ID: NCT02437344 Org: User:

Start: 01/31/15 End: 12/31/16 Due: 12/31/17

Cognitive Training and Neuroplasticity in Mild Cognitive Impairment

Phase: N/A Priority: Normal

NCT ID: NCT03205709 Org: User:

Start: 11/29/17 End: 12/27/21 Due: 12/27/22

Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder

Phase: N/A Priority: Normal

NCT ID: NCT00563992 Org: User:

Start: 01/31/01 End: 10/31/08 Due: 10/31/09

Facilitating Opioid Care Connections

Phase: N/A Priority: Normal

NCT ID: NCT04216719 Org: User:

Start: 03/18/20 End: 04/01/26 Due: 04/01/27

Medication Development for Opioid and Alcohol Abuse

Phase: N/A Priority: Normal

NCT ID: NCT03205423 Org: User:

Start: 08/01/17 End: 12/30/21 Due: 12/30/22

Effect of Baclofen on Marijuana Withdrawal and Relapse

Phase: N/A Priority: Normal

NCT ID: NCT00373295 Org: User:

Start: 05/31/06 End: 01/31/10 Due: 01/31/11

Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil

Phase: N/A Priority: Normal

NCT ID: NCT01845636 Org: User:

Start: 08/31/12 End: 03/31/16 Due: 03/31/17

Kuvan in People With Schizophrenia and Schizoaffective Disorder

Phase: N/A Priority: Normal

NCT ID: NCT01706965 Org: User:

Start: 10/31/12 End: 06/30/16 Due: 06/30/17

Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder

Phase: N/A Priority: Normal

NCT ID: NCT00533117 Org: User:

Start: 03/31/01 End: 12/31/12 Due: 12/31/13

Evaluation of the Communities of Healing Mentorship/Support Group Program: Assessment of Preliminary Efficacy

Phase: N/A Priority: Normal

NCT ID: NCT03317379 Org: User:

Start: 10/01/17 End: 06/30/21 Due: 06/30/22

HIV Counseling Intervention for Methadone-Maintained Patients - 2

Phase: N/A Priority: Normal

NCT ID: NCT00061100 Org: User:

Start: 10/31/99 End: 10/31/03 Due: 10/31/04

Computer-Based Treatment for Social Anxiety Disorder

Phase: N/A Priority: Normal

NCT ID: NCT03415022 Org: User:

Start: 01/30/18 End: 03/31/20 Due: 03/31/21

Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients

Phase: N/A Priority: Normal

NCT ID: NCT00420771 Org: User:

Start: 01/31/07 End: 01/31/11 Due: 01/31/12

Feasibility, Acceptability, and Preliminary Efficacy of a Mobile App (nOCD) for OCD

Phase: N/A Priority: Normal

NCT ID: NCT03476902 Org: User:

Start: 10/27/17 End: 09/30/19 Due: 09/30/20

Sleep Interventions and Neurocognitive Outcomes

Phase: N/A Priority: Normal

NCT ID: NCT05987007 Org: User:

Start: 08/01/25 End: 12/31/27 Due: 12/31/28

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Early Phase II Trials for Cocaine Medication Development - 1	NCT00000317	New York State Psychiatric Institute	user8@example.com	Incompliant	1996-08-31	1999-07-31	2000-07-31	2025-07-01	-	2025-07-14
New Approaches to Cocaine Abuse Medications (A) - 6	NCT00000271	New York State Psychiatric Institute	user2@example.com	Compliant	1995-01-31	2002-10-31	2003-10-31	2025-07-01	-	2025-07-14
A Laboratory Model for Heroin Abuse Medications - 8	NCT00000273	New York State Psychiatric Institute	user4@example.com	Incompliant	1995-08-31	2005-11-30	2006-11-30	2025-07-01	-	2025-07-14
A Gender-Enhanced Pre-Exposure Prophylaxis (PrEP) Information-Motivational Workshop for Young South African Women	NCT04833127	New York State Psychiatric Institute	user2@example.com	None	2021-03-17	2022-12-31	2023-12-31	-	-	2025-07-14
Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression	NCT00564278	New York State Psychiatric Institute	user2@example.com	None	2008-02-29	2013-08-31	2014-08-31	-	-	2025-07-14
Eye Tracking as a Biomarker of Cannabis Effects	NCT04100590	New York State Psychiatric Institute	user2@example.com	None	2019-10-01	2020-01-31	2021-01-31	-	-	2025-07-14
Electroretinogram: a New Human Biomarker for Smoking Cessation Treatment	NCT03213418	New York State Psychiatric Institute	user2@example.com	None	2018-02-01	2022-12-01	2023-12-01	-	-	2025-07-14
Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1	NCT00061087	New York State Psychiatric Institute	user2@example.com	None	1998-02-28	2004-10-31	2005-10-31	-	-	2025-07-14
Pioglitazone for Heroin and for Nicotine Dependence	NCT01395797	New York State Psychiatric Institute	user2@example.com	None	2011-03-31	2014-06-30	2015-06-30	-	-	2025-07-14
Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder	NCT04880278	New York State Psychiatric Institute	user2@example.com	None	2022-03-01	2024-05-08	2025-05-08	-	-	2025-07-14
Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence	NCT02437344	New York State Psychiatric Institute	user2@example.com	None	2015-01-31	2016-12-31	2017-12-31	-	-	2025-07-14
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment	NCT03205709	New York State Psychiatric Institute	user2@example.com	None	2017-11-29	2021-12-27	2022-12-27	-	-	2025-07-14
Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder	NCT00563992	New York State Psychiatric Institute	user2@example.com	None	2001-01-31	2008-10-31	2009-10-31	-	-	2025-07-14
Facilitating Opioid Care Connections	NCT04216719	New York State Psychiatric Institute	user2@example.com	None	2020-03-18	2026-04-01	2027-04-01	-	-	2025-07-14
Medication Development for Opioid and Alcohol Abuse	NCT03205423	New York State Psychiatric Institute	user2@example.com	None	2017-08-01	2021-12-30	2022-12-30	-	-	2025-07-14
Effect of Baclofen on Marijuana Withdrawal and Relapse	NCT00373295	New York State Psychiatric Institute	user2@example.com	None	2006-05-31	2010-01-31	2011-01-31	-	-	2025-07-14
Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil	NCT01845636	New York State Psychiatric Institute	user2@example.com	None	2012-08-31	2016-03-31	2017-03-31	-	-	2025-07-14
Kuvan in People With Schizophrenia and Schizoaffective Disorder	NCT01706965	New York State Psychiatric Institute	user2@example.com	None	2012-10-31	2016-06-30	2017-06-30	-	-	2025-07-14
Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder	NCT00533117	New York State Psychiatric Institute	user2@example.com	None	2001-03-31	2012-12-31	2013-12-31	-	-	2025-07-14
Evaluation of the Communities of Healing Mentorship/Support Group Program: Assessment of Preliminary Efficacy	NCT03317379	New York State Psychiatric Institute	user2@example.com	None	2017-10-01	2021-06-30	2022-06-30	-	-	2025-07-14
HIV Counseling Intervention for Methadone-Maintained Patients - 2	NCT00061100	New York State Psychiatric Institute	user2@example.com	None	1999-10-31	2003-10-31	2004-10-31	-	-	2025-07-14
Computer-Based Treatment for Social Anxiety Disorder	NCT03415022	New York State Psychiatric Institute	user2@example.com	None	2018-01-30	2020-03-31	2021-03-31	-	-	2025-07-14
Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients	NCT00420771	New York State Psychiatric Institute	user2@example.com	None	2007-01-31	2011-01-31	2012-01-31	-	-	2025-07-14
Feasibility, Acceptability, and Preliminary Efficacy of a Mobile App (nOCD) for OCD	NCT03476902	New York State Psychiatric Institute	user2@example.com	None	2017-10-27	2019-09-30	2020-09-30	-	-	2025-07-14
Sleep Interventions and Neurocognitive Outcomes	NCT05987007	New York State Psychiatric Institute	user2@example.com	None	2025-08-01	2027-12-31	2028-12-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance